Mutual of America Capital Management’s Avidity Biosciences RNAM Stock Holding History

Mutual of America Capital Management’s Portfolio RNAM Stock Details RNAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-148,849	Closed	-$6.49M	–	1382
2025 Q3	$6.49M	Sell	148,849 -26,778	-15%	-$1.08M	0.07%	340
2025 Q2	$4.99M	Buy	175,627 +10,808	+7%	+$322K	0.05%	441
2025 Q1	$4.87M	Buy	164,819 +305	+0.2%	+$9.5K	0.06%	434
2024 Q4	$4.78M	Sell	164,514 -483	-0.3%	-$20.2K	0.05%	464
2024 Q3	$7.58M	Sell	164,997 -19,252	-10%	-$835K	0.08%	274
2024 Q2	$7.53M	Buy	184,249 +40,913	+29%	+$1.17M	0.08%	257
2024 Q1	$3.66M	Sell	143,336 -5,866	-4%	-$91.9K	0.04%	634
2023 Q4	$1.35M	Buy	149,202 +15,245	+11%	+$102K	0.02%	1010
2023 Q3	$855K	Buy	133,957 +3,323	+3%	+$28.6K	0.01%	1050
2023 Q2	$1.45M	Buy	+130,634	New	+$1.64M	0.02%	996

Other funds holding RNAM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Mutual of America Capital Management's RNAM Position: Q4 2025 in Review

Mutual of America Capital Management sold out of Avidity Biosciences (RNAM) in Q4 2025, closing a stake of 148,849 shares — an estimated $6.49M sold.

Mutual of America Capital Management first reported a position in RNAM in Q2 2023 and held it in 10 quarters. The position peaked at $7.58M in Q3 2024. 343 funds tracked by Wall St. Rank hold RNAM as of Q4 2025.

Mutual of America Capital Management reported no remaining Avidity Biosciences position as of Q4 2025 after selling out during the quarter.
Mutual of America Capital Management sold 148,849 Avidity Biosciences shares in Q4 2025, an estimated $6.49M.
Mutual of America Capital Management first reported a position in Avidity Biosciences in Q2 2023 and held it in 10 quarters.
Mutual of America Capital Management's Avidity Biosciences position peaked at $7.58M in Q3 2024.
343 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2025.

Based on Mutual of America Capital Management's 13F filing for Q4 2025, filed 10 Feb 2026.